Live Breaking News & Updates on Head Of Global Drug Development|Page 9

Stay updated with breaking news from Head of global drug development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Incyte and MorphoSys AG: Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma


Incyte and MorphoSys AG: Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
Respiratory tract infection
These are not all the possible side effects of MONJUVI.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you:
Have an active infection or have had one recently.
Are pregnant or plan to become pregnant. MONJUVI may harm your unborn baby. You should not become pregnant during treatment with MONJUVI. Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby. ....

United States , Julia Neugebauer , Peter Langmuir , Mike Akimov , Myles Clouston , Jeanette Bressi , Thomas Biegi , Catalina Loveman , Christine Chiou , Jenifer Antonacci , Head Of Global Drug Development , Janssen Biotech Inc , Xencor Inc , World Health Organization , Group Vice , Drug Administration , Janssen Research Development , Morphosys Us Inc , Exchange Commission , Us Communications , Public Affairs , European Medicines Agency , Decision Resources Group , Prime Standard Segment , Group Vice President , Oncology Targeted Therapeutics ,

MorphoSys AG: MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma


MorphoSys AG: MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
Respiratory tract infection
These are not all the possible side effects of MONJUVI.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you:
Have an active infection or have had one recently.
Are pregnant or plan to become pregnant. MONJUVI may harm your unborn baby. You should not become pregnant during treatment with MONJUVI. Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby. ....

United States , Julia Neugebauer , Peter Langmuir , Mike Akimov , Myles Clouston , Jeanette Bressi , Thomas Biegi , Catalina Loveman , Christine Chiou , Jenifer Antonacci , Head Of Global Drug Development , Janssen Biotech Inc , Xencor Inc , World Health Organization , Group Vice , Drug Administration , Janssen Research Development , Morphosys Us Inc , Exchange Commission , Us Communications , Public Affairs , European Medicines Agency , Decision Resources Group , Prime Standard Segment , Group Vice President , Oncology Targeted Therapeutics ,